检验

订阅

MedSci主页 / 所有栏目 / 检验

Clinica Chimica Acta：利用构象特异性抗体和FTIR光谱技术监测衰老过程中的血浆蛋白聚集情况

2020-04-12 MedSci原创 MedSci原创

衰老过程；血浆蛋白聚集
关注

已有研究通过不同的模型对衰老过程中蛋白质稳定性丧失进行了很好的描述，但关于衰老过程中生物体液中蛋白质聚集水平的研究却仍很少。

已有研究通过不同的模型对衰老过程中蛋白质稳定性丧失进行了很好的描述，但关于衰老过程中生物体液中蛋白质聚集水平的研究却仍很少。因此，本研究的目的是使用两种不同的方法:利用构象特异性抗体和FTIR光谱分析来评估与年龄相关的蛋白质在人血浆中的聚集模式。其中，FTIR光谱分析已被广泛应用于生物医学研究中，研究蛋白质在健康和疾病中的构象变化。

研究人员先采用位点印迹分析对来自葡萄牙阿威鲁地区的初级保健基础队列的样本进行分析，随后使用构象特异性抗体进行免疫检测，并获取FTIR光谱。免疫印迹分析显示，随着年龄的增长，人血浆中的蛋白质构象原纤化前低聚物逐渐减少和原纤化结构增加。这一发现也得到了PLS-R多变量分析FTIR数据的支持，其中可以观察到供体年龄与血浆蛋白二级结构之间的正相关关系。

研究表明，来自较年轻供体的样品的特征是具有反平行的β-折叠结构，而分子间β-折叠则具有较老的样品特征。 排除与年龄相关的合并症可改善蛋白质构象特征与衰老之间的相关性。结果揭示了中老年人血浆蛋白的结构变化，证实了蛋白质聚集随年龄的变化，支持了FTIR作为研究老年期蛋白质稳态的可靠方法的适用性。

原始出处：

Sandra Magalhães，Dário Trindade，Monitoring plasma protein aggregation during aging using conformation-specific antibodies and FTIR spectroscopy

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849889, encodeId=12da1849889cd, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Nov 20 11:52:55 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899370, encodeId=e54018993e02c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Feb 16 20:52:55 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926503, encodeId=cc6d192650363, content=<a href='/topic/show?id=891089221dc' target=_blank style='color:#2F92EE;'>#血浆蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89221, encryptionId=891089221dc, topicName=血浆蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Dec 07 10:52:55 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526467, encodeId=ff39152646e1f, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Tue Apr 14 11:52:55 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
    2020-11-20 windight

    #CTA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1849889, encodeId=12da1849889cd, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Nov 20 11:52:55 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899370, encodeId=e54018993e02c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Feb 16 20:52:55 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926503, encodeId=cc6d192650363, content=<a href='/topic/show?id=891089221dc' target=_blank style='color:#2F92EE;'>#血浆蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89221, encryptionId=891089221dc, topicName=血浆蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Dec 07 10:52:55 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526467, encodeId=ff39152646e1f, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Tue Apr 14 11:52:55 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
    2021-02-16 jinweidong

    #特异性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1849889, encodeId=12da1849889cd, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Nov 20 11:52:55 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899370, encodeId=e54018993e02c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Feb 16 20:52:55 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926503, encodeId=cc6d192650363, content=<a href='/topic/show?id=891089221dc' target=_blank style='color:#2F92EE;'>#血浆蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89221, encryptionId=891089221dc, topicName=血浆蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Dec 07 10:52:55 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526467, encodeId=ff39152646e1f, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Tue Apr 14 11:52:55 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
    2020-12-07 zhaohui6731

    #血浆蛋白#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1849889, encodeId=12da1849889cd, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Nov 20 11:52:55 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899370, encodeId=e54018993e02c, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Tue Feb 16 20:52:55 CST 2021, time=2021-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926503, encodeId=cc6d192650363, content=<a href='/topic/show?id=891089221dc' target=_blank style='color:#2F92EE;'>#血浆蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89221, encryptionId=891089221dc, topicName=血浆蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Dec 07 10:52:55 CST 2020, time=2020-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526467, encodeId=ff39152646e1f, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Tue Apr 14 11:52:55 CST 2020, time=2020-04-14, status=1, ipAttribution=)]
    2020-04-14 hyf032

    #特异性抗体#

    0